RankAlpha logo
Back to Rankings

ARVN

ArvinasB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The post-print bull read is that first-in-class PROTAC approval plus the planned Rigel handoff lets Arvinas redirect focus toward ARV-102, ARV-806 and ARV-393 while cash runway guidance extends into 2H28 [#8-K-2026-05-12]. Secondary reaction was constructive: StockAnalysis showed BofA raising its target to $16 from $14, BTIG to $18 from $16, and Barclays to $20 from $18 after the update.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -0.1.
What can break
ARV-102’s next step in PSP is explicitly pending FDA feedback, so delay or narrower trial scope would pressure one of the cleanest 2H26 catalysts.
Momentum
14
Value
57
Sentiment
85
Setup hits (3d)
— · Net —
AI TargetsBase $11.00 · Bull $15.50 · Bear $6.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net —
Target $15.07
Why
Momentum14 · Δ7d +15.5
Value57 · Δ7d -0.3
Sentiment85 · Δ7d -0.1
So what
Strength-led posture. Favor watchlist adds and disciplined entries.
Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits
Lead driver: Sentiment · See AI snapshot
Momentum
14
26% active weight
Current posture
7d trendImproving
Δ7d
+15.5
Δ21d
+19.6
Value
57
39% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.0
Sentiment
85
34% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-1.0
Why this grade

Composite grade B. Momentum 13.6 / Value 57.2 / Sentiment 85.3

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$516.82M
Beta
1.88
Shares Out
64.52M
P/E (TTM) · Derived
-7.0
P/S (TTM)
2.30
P/FCF (TTM) · Derived
-2.16
Rev YoY
-91.7%
EPS YoY
-178.9%
Gross Margin
+94.4%
Op Margin
-32.7%
Net Debt
-$676.3M
Current Ratio
5.44
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology